Interferon α-2a and Dacarbazine in Melanoma
John M. Kirkwood(UPMC Hillman Cancer Center), Robert J. Spiegel, William A. Robinson(University of Colorado Anschutz Medical Campus), J. Costanzi(Thompson Cancer Survival Center), Meredith Grimm, James L. Speyer(Breast Center), Marc S. Ernstoff(National Cancer Institute), P Pouillart(Institut Curie), A. E. Giuliano(University of California, Los Angeles), Richard A. Gams(Breast Center)
Cited by 47
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
|Journal for ImmunoTherapy of Cancer|2017|2k
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
|Journal for ImmunoTherapy of Cancer|2021|804
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
|Journal of Clinical Oncology|1997|652